EP2184279A1 — Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity and intermediate thereof
Assigned to Shionogi and Co Ltd · Expires 2010-05-12 · 16y expired
What this patent protects
An optically active 4-phenylthiazole derivative having a thrombopoietin receptor agonist activity and a pharmaceutical composition containing the present compound as an active ingredient are created, and a platelet production regulating agent which can be orally administered is p…
USPTO Abstract
An optically active 4-phenylthiazole derivative having a thrombopoietin receptor agonist activity and a pharmaceutical composition containing the present compound as an active ingredient are created, and a platelet production regulating agent which can be orally administered is provided. Disclosed is a pharmaceutical composition containing, as an active ingredient, an optically active compound represented by the formula: wherein, R 1 is a halogen atom or C1-C3 alkyloxy; R 2 is C1-C8 alkyl R 3 is C1-C8 alkyl R 4 and R 5 are each independently a fluorine atom or chlorine atom; R 6 is C1-C3 alkyl or C1-C3 alkyloxy * indicates that a carbon atom marked with an asterisk is an asymmetric carbon, a pharmaceutically acceptable salt thereof, or a solvate thereof.
Drugs covered by this patent
- Mulpleta (LUSUTROMBOPAG) · Vancocin Italia
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.